Chargement en cours...
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers have emerged as key predictive biomarkers in EGFR tyrosine kinase inhibitor (TKI) treatment. However, a few patients with wild-type EGFR also respond to EGFR TKIs. This study investigated the factors predict...
Enregistré dans:
| Publié dans: | Tuberc Respir Dis (Seoul) |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6304331/ https://ncbi.nlm.nih.gov/pubmed/29926551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2018.0004 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|